Cod Liver Oil — Body Handbook

Supplements · §494

Cod Liver Oil

Cod liver oil is the original fish oil — the one your grandmother kept on the counter, the one that cured rickets before anyone knew vitamin D existed. It is also the one with a ceiling. A teaspoon delivers a coherent dose of omega-3, vitamin D, and vitamin A in their natural ratios; two teaspoons starts to push the vitamin A toward levels linked to hip fractures and, in pregnancy, to malformations. The big-money omega-3 trials at the dose a teaspoon supplies have come back null on heart attacks, which means CLO earns its place by what it actually does — closing the omega-3 and winter vitamin D gap in people who are short on both — not by what supplement-aisle marketing wants it to do. Treat it as a small daily floor-lift, pick a fresh and tested product, and don't stack it on top of a multivitamin without doing the math.

Do · Daily Evidence Emerging Chapter Supplements

Cheap, simple, traditional — and modest. The strongest case is for low-fish-diet readers at northern latitudes where winter sun doesn't make vitamin D; less compelling if you already eat fish twice a week and live in Florida. The catch worth knowing up front is the vitamin A: more is not better, and the threshold where it starts working against bone (and, in pregnancy, against the baby) is reachable from CLO alone if you double-dose or stack it with a multivitamin.

Three things are working at once when you take a teaspoon of cod liver oil, and they explain almost everything CLO does and doesn't do.

The first two are the long-chain omega-3 fatty acids, EPA and DHA. These slot into the membranes of every cell in your body — most heavily in brain, retina, heart muscle, and the white blood cells that drive inflammation — and gently shift the chemical signals those cells produce in a less-inflammatory direction. EPA is the one doing most of the work on triglycerides and inflammatory tone; DHA is more of a structural fatty acid for nerves and eyes. The cod doesn't make them; the algae the cod eats does, and the cod concentrates them.

The third is vitamin D, which the cod stores in its liver because cod live in a place with no sunshine. In you, vitamin D becomes a hormone that tells your gut to absorb calcium, your muscles to work properly, and your immune cells to behave. Below a certain blood level — roughly 30 ng/mL of 25-hydroxyvitamin D, what your doctor measures — you fall more, you fracture more, you may catch more colds. At high latitude in winter, your skin doesn't make any vitamin D at all for months; the question is just where you get it from.

Riding alongside is a fourth ingredient that is both the point and the problem: preformed vitamin A as retinol, the active form your body uses directly without having to convert it from carrots. It supports skin, vision, and immune function. It also accumulates in your liver if you take too much for too long, and that ceiling is the single most important thing about cod liver oil as a daily habit.

What it actually does — and the dose at which it does it

The fairest summary of the modern evidence: the active ingredients in cod liver oil work, but mostly at doses or in populations where the gap to be closed was real to start with. Take a teaspoon, and what you get is statistical sufficiency on three nutrients that a lot of people are short on. That is not nothing — but it is also not a heart-attack-prevention drug.

The biggest question readers bring is whether fish oil prevents cardiovascular disease. Three large, well-run trials at the dose range a teaspoon of cod liver oil supplies — roughly a gram of EPA plus DHA per day — came back null. The VITAL trial in 25,000 healthy adults found no reduction in major cardiovascular events Manson et al. 2019; ASCEND in 15,000 diabetics found the same ASCEND 2018; the Cochrane review pooling 86 trials concluded that adding EPA and DHA has little or no effect on overall death rates Abdelhamid et al. 2020. The one trial showing a clear cardiovascular benefit used four grams of pure EPA per day — a prescription drug, not a food, not chemically what cod liver oil contains Bhatt et al. 2019. A teaspoon of CLO cannot reproduce that effect; you would have to drink half a bottle, which the vitamin A ceiling makes impossible.

Where the evidence is more interesting is the parts of the body the cardiovascular trials weren't built to measure. In coastal Norway, where winter sun makes essentially zero vitamin D, regular cod liver oil use is one of the strongest predictors of having adequate blood levels through the dark months Brustad et al. 2004. In older adults at risk of falling, vitamin D at the dose a daily teaspoon provides — around 800 IU — cuts falls by about a fifth Bischoff-Ferrari et al., BMJ 2009; that is the cleanest single benefit of the vitamin D fraction. In people with rheumatoid arthritis, a high CLO dose (10 grams a day for nine months) let nearly 40% of them cut their daily anti-inflammatory dose by a third without losing disease control, compared to 10% on placebo Galarraga et al. 2008. And in Norwegian infants given cod liver oil in their first year of life, the risk of later type 1 diabetes was about a quarter lower than in infants who weren't, an effect the study authors attributed to vitamin D and the long-chain omega-3s together Stene and Joner 2003.

Add it up, and the honest read is: real but modest. Sufficiency in three nutrients that matter, plus a specific anti-inflammatory effect at high doses. Not a shortcut to a different life.

What it looks like if you're short on what's inside

The stakes for CLO are quiet, which is exactly why they get ignored. The reader who could most use it doesn't notice they could most use it.

If you live north of about Madrid or Boston, work indoors, and don't eat fish twice a week, your blood vitamin D probably falls below the official adequacy threshold from October until April every year. You don't feel anything specific. You might catch the cold that goes through the office in February instead of dodging it. If you're over 65, you fall a little easier on the icy step outside the grocery store; the hip you fracture in your seventies traces in part to a decade of winter D in the low twenties when it should have been in the thirties Bischoff-Ferrari et al. 2009. None of this is a felt deficit. It is a background slope.

The omega-3 side is even quieter. Your joints click a little more than they should. The cold you got in November ran longer than it had to. You bruise easier than the person next to you on the train. None of these are alarms. They are a tax that fish-eating populations pay less of and that low-fish-eating populations carry without naming.

What a teaspoon of CLO does, over months, is reduce that background tax by a small but real amount. The version of your year with adequate winter D and an omega-3 index in the healthy range is not transformed; it is slightly less inflamed, with a measurable hip-fracture risk reduction in old age and one less reason to feel run-down in February. That is the realistic upside, and it is the upside worth taking — but only if you do not, in trying to take more of it, walk into the ceiling on the other side.

How to take it

One teaspoon (5 mL) of a regular-strength liquid product, once a day, with a meal that contains some fat. Or one to two standard capsules. That's the whole protocol, and the size of it is set not by how much omega-3 you'd ideally want, but by how much vitamin A you can safely accumulate over years.

If you want a bigger omega-3 dose than that — for example because your doctor wants your triglycerides lower — do not double the CLO. Add a vitamin-A-free fish-body-oil product on top, or switch to one entirely. CLO is the maintenance vehicle; it is not the right tool for chasing pharmaceutical-grade doses.

When to skip it

Three groups should think hard before taking CLO at standard doses, and one group should not take regular-formulation CLO at all.

If you are on a blood thinner — warfarin, apixaban, rivaroxaban, dabigatran — the omega-3 fraction at high doses can prolong bleeding time and at very high doses (4 g/day, well above CLO range) can mildly raise the risk of atrial fibrillation. At a teaspoon a day the interaction is rarely clinically meaningful, but tell your prescribing clinician you've started it and don't stack additional fish-oil supplements without checking.

If you have hemochromatosis or another iron-overload condition, vitamin A modestly enhances dietary iron absorption — a small concern, but worth flagging to the clinician managing your iron load.

If you have a known fish allergy, ask before starting; the offending proteins are largely removed during oil refining but cannot be assumed gone.

And separately from contraindications: if you already eat oily fish (salmon, sardines, mackerel) three or more times a week and your vitamin D status is good year-round, the marginal value of CLO is small. You aren't risking anything by taking it; you just may not be buying much.

What most guides get wrong

Three things confuse this whole category, and clearing them up is most of what makes CLO usable.

"It's basically the same as fish oil." Mechanically yes, practically no. Refined fish oil is concentrated EPA and DHA from the bodies of small oily fish, with the vitamins removed. Cod liver oil is the liver, with the vitamins still in. The vitamins are why CLO has a ceiling that fish-body oil does not — and why the trick of taking three or four servings to chase a higher omega-3 dose, which works for fish oil, becomes dangerous for CLO over time Feskanich et al. 2002.

"Fermented or unrefined cod liver oil is the better, more authentic version." There is no controlled evidence that fermented or "raw" CLO confers additional benefit over a properly produced standardised product. There is independent testing showing that some of the higher-priced traditional-craft CLO products are heavily oxidised by the time they reach the consumer — i.e., partially rancid — while well-handled refined products are not Albert et al. 2015. The marketing is doing the work; the science isn't following.

"CLO is the same as a vitamin D supplement." Only at sufficient dose. A teaspoon of typical CLO supplies 400-1,000 IU of vitamin D, which is fine maintenance for most adults. But if you're documented-deficient and need 2,000-4,000 IU a day to get back into the adequate range — which is common at high latitude or in dark-skinned individuals — you cannot get there with more CLO, because the vitamin A would land you in trouble first. Take a standalone D drop or capsule for the corrective dose and let CLO be the steady-state vehicle.

Where this goes wrong in practice

Three failure patterns account for most of the "I took CLO for a year and felt nothing" — or worse, "I took CLO for a year and got hurt" — stories.

The bottle is rancid before you finish it. EPA and DHA are unstable; left at room temperature, exposed to light, or kept past their freshness window, they oxidise into compounds with their own toxicity. Independent testing of 32 fish-oil products in New Zealand found that more than 80% exceeded a recommended limit on peroxide value, and half exceeded a total-oxidation limit; only 8% met every freshness criterion Albert et al. 2015. Cod liver oil sits in the same boat. The signal you can detect at home is taste: fresh CLO tastes neutral or mildly oceanic. Rancid CLO tastes sharp, paint-like, or strongly fishy in a way that lingers in your mouth. A burp that smells like spoiled oil is a real flag — not normal, not the price of admission, a reason to throw out the bottle.

Vitamin A creeps up without you noticing. The reader takes a teaspoon of CLO every morning, takes a multivitamin in the same breath because everyone says to, and routinely eats liver pâté on toast because they read it was a superfood. Each by itself is reasonable. Together they can put preformed retinol intake well above the safe upper limit for years, and the consequence shows up not as a daily symptom but as a 50% higher hip-fracture risk decades later Feskanich et al. 2002, and in women considering pregnancy, as a malformation risk above what any of them would accept knowingly Penniston and Tanumihardjo 2006. The fix is simple — do the math once, look at the retinol on each label, don't double-count — but almost nobody does it.

Taking it as if it were a heart-attack-prevention drug. The fish-oil-prevents-heart-attacks narrative survives in supplement marketing well past where the evidence took it. At the dose CLO supplies, the modern trials are null on cardiovascular events Manson et al. 2019 ASCEND 2018 Cochrane 2020. If your doctor wants your triglycerides aggressively lowered or you have established heart disease, the right answer is either a much higher dose of an actual fish-body oil, or a prescription omega-3 such as icosapent ethyl — not more CLO.

What else you could take instead

The choice is not "CLO or nothing." Once you know what you actually want, the right product often isn't CLO.

You want omega-3 only, no vitamins: a third-party-tested refined fish-body oil (from anchovy, sardine, or menhaden), or — if you're vegan or vegetarian — an algal EPA+DHA product. Both let you take more than a teaspoon's worth of omega-3 without the vitamin A ceiling. Check the label for actual EPA+DHA milligrams per serving, not just "fish oil" weight, and look for the same independent freshness certifications.
You want a pharmaceutical-grade triglyceride or cardiovascular dose: ask your doctor about icosapent ethyl (Vascepa), the EPA-only prescription at 4 g/day that produced the one clear cardiovascular benefit in the modern trial era Bhatt et al. 2019. This is a drug, not a supplement, and it's not what's in a CLO bottle.
You want vitamin D only: a standalone D₃ drop or capsule, dosed against your blood level. This is the right tool if you're correcting a deficiency, because you can adjust the dose without dragging vitamin A along.
You want a vitamin A source: a diet that includes orange/yellow vegetables, leafy greens, eggs, and dairy gets you to adequacy via beta-carotene, which your body converts only as needed and does not accumulate toxically. Routine vitamin A supplementation is rarely necessary in well-fed adults.
You can just eat the fish: two to three servings a week of fatty fish (salmon, sardines, mackerel, herring) approximates a teaspoon of CLO on omega-3 grounds, gives you protein and selenium too, and has the best epidemiological track record of any approach. The supplement is for the weeks the fish doesn't happen.

Buying it, storing it, swallowing it

Cost is the easiest part. A reasonable liquid CLO runs $15-40 for a 250 mL bottle that lasts about two months at a teaspoon a day — call it $50-100 a year for a quality product. Capsules are pricier per dose but worth it if the taste is the obstacle that keeps you from taking it.

What to actually look for on the shelf, in order:

An independent third-party freshness or quality mark — most commonly IFOS (International Fish Oil Standards) or a statement of compliance with the GOED voluntary monograph for oxidation values. This is the closest thing the consumer market has to a guarantee the oil isn't rancid in the bottle.
A "bottled on" or "best by" date that is recent, and a stated number of months of shelf-life after opening (usually 60-90 days refrigerated).
An opaque or dark bottle. Clear glass with CLO inside is a freshness liability.
EPA + DHA totals printed in milligrams per serving — not just "fish oil 1000 mg," which tells you nothing about active content.
Vitamin A and D content per serving, in IU or mcg, both visible on the label. If you cannot find these numbers, skip the bottle — you cannot dose it safely without them.

The flavoured liquid versions (lemon, mint, orange) mask the taste effectively. The straight stuff has acquired a folklore status of being unpleasant; it's not as bad as the reputation, but it's not nothing.

Smell-test on first opening: a clean fishy or oceanic note is fine. Anything that reads as paint, solvent, putty, or a sharp fishy that lingers in the throat is the product telling you it's already oxidising. Return it; this is a quality-control failure, not a tolerance you build up.

Why your grandmother had a bottle

Cod liver oil treated the rickets crisis of the industrial city before anyone knew what rickets was. Coastal fishing families in northern Europe had been pressing oil from cod livers for centuries — for lamps, for leather, for the children — and noticed empirically that their kids didn't get the bone-bending deformity that crippled the children of inland factory towns. In 1919 the Manchester pediatrician Edward Mellanby produced rickets in laboratory dogs and cured it with cod liver oil; within a decade vitamin D had been isolated and the mechanism was named.

By the 1930s CLO was a staple of pediatric practice across North America and northern Europe. Norway's state ration of tran — cod liver oil — to schoolchildren, and the UK's post-war welfare-food scheme, institutionalised it for two generations. Then milk fortification with vitamin D from the 1940s, and standalone vitamin D supplements from the 1960s, displaced it; refined fish-body oil rose in the 1990s on the back of the omega-3 cardiovascular hypothesis. The current revival is a smaller, traditional-foods-coded niche — half nostalgia, half a genuine intuition that the whole-food version of three nutrients you'd otherwise take in three bottles has something the bottles don't.

What you get back if it fits you

Three months in, on a teaspoon a day, in someone who started short: the omega-3 index — the percentage of EPA and DHA in your red blood cell membranes, which you can measure if you want — drifts from somewhere in the low fours into the six-to-eight range that epidemiology associates with the lowest cardiovascular event rates. Blood 25-hydroxyvitamin D, the standard lab measure of vitamin D status, lifts from the low twenties into the thirties — across the threshold the falls-prevention literature uses as the line where the protective effect appears Bischoff-Ferrari et al. 2009. Neither change is anything you feel directly. They are floor changes — the kind that show up in averages over years, not in mornings.

What you might feel, in the right subgroup: less joint stiffness on cold mornings if you had inflammatory joints to start with; one less cold than your colleagues over a winter; less fatigue if your vitamin D was genuinely deficient and the correction was overdue. People with rheumatoid arthritis taking a much higher dose — about ten times what this entry recommends, taken under medical supervision — find that about four in ten can cut their daily anti-inflammatory medication by a third without their disease getting worse Galarraga et al. 2008. That is the highest-leverage payoff CLO delivers, and it is also the smallest population it applies to.

For the broader reader, the right framing is unglamorous: a small daily act that quietly lifts a couple of floors. The fish you didn't eat that week, made up for. The winter sun your skin didn't get, partly compensated. Not a transformation. A piece of plumbing kept up to spec, year after year — which is what most of the best things in this catalogue actually are.

Related decisions worth their own look

Vitamin D supplementation as a separate decision — how to dose by blood level, not by daily IU, and when CLO isn't enough on its own.
Fatty fish in the diet — two to three servings a week of salmon, sardines, mackerel, or herring is the closest thing to a substitute for the omega-3 fraction of CLO.
Omega-3 index testing — the home or lab fingerstick test that tells you whether your EPA+DHA tissue status is actually in the range the epidemiology calls protective.
Icosapent ethyl as a prescription cardiovascular intervention — a different drug at a different dose with a different evidence base from food-grade omega-3.
Vitamin A from beta-carotene vs preformed retinol — why the carrot version doesn't carry the toxicity ceiling that the cod liver version does.

Substance and claimed effects

Cod liver oil (CLO) is the oil pressed from the liver of Atlantic cod (Gadus morhua) and related gadoids. It is the historical antecedent of modern refined fish-oil supplements: the same long-chain omega-3 fatty acids — eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) — but carried alongside the liver's stored fat-soluble vitamins, principally preformed vitamin A (retinyl esters) and vitamin D₃ (cholecalciferol). A typical regular-strength product delivers roughly 600-1000 mg combined EPA+DHA, 800-1500 mcg retinol activity equivalents (RAE) of vitamin A (~2,500-5,000 IU), and 10-25 mcg (400-1000 IU) of vitamin D₃ per 5 mL teaspoon, although content varies widely by brand and by whether the manufacturer has standardised the vitamins after molecular distillation. Three distinct products live under the "fish oil" umbrella and must be kept separate: cod liver oil (liver-derived, A+D co-delivered, traditional whole-food form), refined fish-body oil (concentrated EPA+DHA from muscle/body of small pelagics like anchovy, sardine, menhaden — typically vitamin-free), and algal omega-3 (vegan EPA/DHA from cultured microalgae). Pharmaceutical EPA-only icosapent ethyl (Vascepa) and EPA+DHA carboxylic-acid formulations are a fourth category, distinct again.

The claimed effects in scope for this entry — held jointly to the consequences the substance plausibly produces and the consequences readers actually ask about — are: improvement of omega-3 index and EPA/DHA tissue status; correction of vitamin D insufficiency, with downstream effects on bone, falls, and (more contested) immune function; vitamin A status as both contribution and ceiling-risk; modest reductions in serum triglycerides and inflammatory markers (CRP, leukotriene B₄) at typical doses; an NSAID-sparing effect in rheumatoid arthritis at high CLO doses; possible blood-pressure effect; and the two product-specific hazards — vitamin A overload at higher intakes and lipid oxidation in poorly stored or stale products. Cardiovascular event reduction is in scope as a question (does CLO prevent heart attacks?) and the honest answer is "not at the doses CLO supplies." Cancer prevention and pregnancy/offspring effects are touched but not the entry's focus.

Evidence by addressing question

mechanism

Science. EPA and DHA incorporate into membrane phospholipids, displacing arachidonic acid and shifting eicosanoid synthesis toward less inflammatory 3-series prostaglandins, 5-series leukotrienes, and toward specialised pro-resolving mediators (resolvins, protectins, maresins). DHA is a structural lipid of neuronal and retinal membranes; EPA dominates the anti-inflammatory and triglyceride-lowering action. Vitamin D₃ is hydroxylated to 25-OH-D in the liver and to 1,25-(OH)₂-D in the kidney; the active form binds the nuclear vitamin D receptor and regulates ~2,000 genes including those for intestinal calcium absorption, osteoblast and osteoclast activity, and components of innate and adaptive immunity. Retinol from CLO is esterified, packaged into chylomicrons, stored in the liver, and released as needed; the active metabolite retinoic acid binds RAR/RXR nuclear receptors governing epithelial differentiation, immune cell function, and embryonic patterning. All three nutrients arrive in CLO bound to the natural triacylglycerol or ester forms in which they are most bioavailable.

Practice / clinical consensus. Mechanism is uncontroversial. The American Heart Association continues to characterise EPA+DHA as mechanistically relevant to triglyceride-lowering and to membrane biology, while distinguishing this from cardiovascular event reduction at non-pharmacological doses Siscovick et al. 2017.

evidence

Science — omega-3 cardiovascular outcomes. The body of evidence on EPA+DHA and cardiovascular events is now mature and consistent in its messiness. The 2020 Cochrane review of 86 randomised trials concluded that increasing EPA and DHA intake has little or no effect on all-cause mortality (high-certainty evidence) and only a small reduction in cardiovascular events and coronary mortality (moderate-certainty) Abdelhamid et al. 2020. The large primary-prevention trials largely missed their primary endpoints: VITAL (n=25,871, 1 g/day EPA+DHA) showed no reduction in major cardiovascular events or cancer over 5.3 years Manson et al. NEJM 2019; ASCEND (n=15,480 diabetics, 1 g/day) likewise null on serious vascular events ASCEND 2018. The two high-dose secondary-prevention trials diverged: REDUCE-IT (4 g/day pure EPA, icosapent ethyl) cut a composite cardiovascular endpoint by 25% (HR 0.75, p<0.001) Bhatt et al. NEJM 2019; STRENGTH (4 g/day mixed EPA+DHA carboxylic acid vs corn-oil placebo) was null (HR 0.99) and was stopped early for futility Nicholls et al. JAMA 2020. The contrast is unresolved — it may reflect EPA-vs-DHA differences, the choice of placebo (mineral oil in REDUCE-IT was likely not inert), or chance. For CLO, the directly relevant takeaway: at the 1 g/day EPA+DHA range a teaspoon delivers, expected event reduction is small if real at all.

Science — triglycerides, inflammation, blood pressure. Triglyceride-lowering is dose-dependent and reproducible: ~5-10% reduction at 1 g/day, ~25-30% at 4 g/day. CRP and IL-6 reductions are modest at typical CLO doses. Blood pressure effects are small (~2 mmHg systolic) at fish-oil doses comparable to CLO.

Science — vitamin D status. Observational and intervention work in northern Norway shows that regular CLO use is one of the strongest dietary predictors of winter 25-OH-D status at high latitude, where cutaneous synthesis is essentially zero from October to March Brustad et al. 2004. A teaspoon supplying 400-1000 IU D₃ is in the same dose range as the IOM RDA (600 IU adults, 800 IU 70+) and reliably raises serum 25-OH-D in deficient individuals.

Science — bone, falls, fracture. The fall-prevention case rests on vitamin D, not on omega-3. Bischoff-Ferrari's BMJ meta-analysis pooled fall-prevention trials and found ~19% relative risk reduction at supplemental doses ≥700-1000 IU/day Bischoff-Ferrari et al. BMJ 2009. CLO at 1-2 tsp/day sits squarely in that dose range. The countervailing bone signal is preformed vitamin A: in the Nurses' Health Study (72,337 women, 18-year follow-up), women in the highest quintile of retinol intake (≥3,000 mcg/day) had a 48% higher hip-fracture risk than the lowest quintile Feskanich et al. JAMA 2002. Multi-teaspoon CLO doses, particularly with a multivitamin or fortified foods stacked on top, can land in this zone.

Science — rheumatoid arthritis. Galarraga's nine-month, dual-centre, double-blind RCT in 97 RA patients gave 10 g/day CLO (delivering ~2.2 g n-3 fatty acids) vs air-filled placebo; 39% of the CLO group reduced their daily NSAID dose by >30% vs 10% of placebo (p=0.002), with no loss of disease control Galarraga et al. Rheumatology 2008. The dose used is well above casual supplementation; the effect is real but earned.

Science — pregnancy and offspring. Two Scandinavian observational lines suggest first-year offspring benefits from maternal/infant CLO use. Stene and Joner's Norwegian case-control study found that cod liver oil given to infants in the first year was associated with lower risk of childhood-onset type 1 diabetes (OR 0.74, 95% CI 0.56-0.99); maternal CLO use in pregnancy showed a similar but weaker trend Stene and Joner 2003. Icelandic observational data linked CLO in early pregnancy to higher birthweight after adjustment for gestational length Olafsdottir et al. 2005. Both are observational and confounded by health-conscious user behaviour; neither warrants high evidence weight on its own, but the pattern is suggestive given mechanism (DHA accretion, vitamin D adequacy).

Community / lay evidence. CLO is one of the longest-running self-administered nutritional traditions in northern Europe and the British Isles — institutionalised in Norway through the Tran (cod liver oil) ration given to schoolchildren and the post-war UK welfare-food scheme. Modern community signal (Weston A. Price Foundation, traditional-foods practitioners, fermented/high-vitamin CLO advocates) tends to overclaim the differential value of unrefined or fermented preparations relative to standardised products; the evidence for fermentation-specific benefit is essentially absent and at least one fermented CLO brand has been independently tested as rancid.

protocol

Science / practice. The natural target dose is set by two competing constraints: enough EPA+DHA and D₃ to matter, capped by vitamin A. Most regular CLO products converge on 5 mL (1 teaspoon) daily as the sensible default — typically ~600-900 mg combined EPA+DHA, ~10-25 mcg (400-1000 IU) D₃, and ~800-1500 mcg retinol. Two teaspoons doubles every value; at three teaspoons many products approach the 3,000 mcg RAE adult vitamin A upper intake limit set by the Institute of Medicine Penniston and Tanumihardjo 2006. Taking with a fat-containing meal improves absorption modestly. Refrigerate after opening; once oxidised, the dose is potentially harmful (see contraindications below).

contraindications

Pregnancy. Preformed vitamin A is teratogenic at high doses (cranial-neural-crest, cardiac, thymic malformations). The threshold is contested but ≥3,000 mcg/day in the periconceptional period has been associated with increased malformation risk. Many CLO products deliver this in 2-3 teaspoons, especially when stacked with prenatal multivitamins that already contain retinol. Some traditional-medicine advice to take CLO in pregnancy predates this concern; the safer modern practice is to use a vitamin-A-free omega-3 plus a separate vitamin D supplement during pregnancy, or to switch to a CLO product with the vitamin A removed.

High-dose vitamin A states. Chronic hypervitaminosis A (headache, bone pain, hair loss, hepatic injury, raised intracranial pressure) is a real entity at sustained intakes >7,500-10,000 mcg/day; rare at standard CLO dosing, achievable at multi-teaspoon CLO plus retinol-containing multivitamins Penniston and Tanumihardjo 2006. Hip-fracture risk rises within the high-but-non-toxic range Feskanich et al. 2002.

Anticoagulation. EPA+DHA at high doses prolong bleeding time; at typical CLO doses the effect is subclinical, but interaction with warfarin or DOACs warrants checking with the prescribing clinician. At REDUCE-IT-scale doses (4 g/day), atrial fibrillation incidence rose.

Hemochromatosis. Vitamin A modestly enhances iron absorption; not a typical concern but worth flagging for iron-overload patients.

Fish allergy. Rare but documented; cross-reactive proteins are largely removed during refining but cannot be assumed absent.

misconceptions

Three recur. First, "CLO is just fish oil with vitamins" — true mechanically, dispositive practically: the vitamins set the dose ceiling and rule out the trick of taking more to chase the EPA+DHA effect size used in trials like REDUCE-IT. Second, "fermented or unrefined cod liver oil is superior" — there is no controlled evidence for this and at least one fermented brand has been independently shown to be heavily oxidised; "raw" or "unprocessed" sells well but does not deliver more useful active nutrients than a standardised modern product. Third, "CLO replaces a vitamin D supplement at any latitude" — only true at sufficient dose; readers at high latitude with documented deficiency often need more D than a teaspoon of CLO delivers, and the vitamin A ceiling makes it impossible to chase the D target with more CLO.

failure-modes

Oxidation. EPA and DHA are highly unsaturated and oxidise readily into aldehydes (4-HNE), epoxides, and other secondary peroxidation products with their own toxicity. Albert's 2015 testing of 32 New Zealand fish-oil products found 83% exceeded the GOED voluntary peroxide-value limit and 50% exceeded total oxidation (TOTOX) recommendations; only 8% met all three oxidation criteria; most also under-delivered on labeled EPA+DHA content Albert et al. 2015. Cod liver oil shares the same liability; some traditional-craft CLO products have tested worse than standardised body-oil products in independent assays. The signal a consumer can detect is taste: fresh CLO tastes neutral or mildly oceanic; rancid CLO tastes sharp, paint-like, or "fishier" than it should. A burp that smells like spoiled oil is a meaningful flag, not normal.

Vitamin A creep. The most common silent failure mode is the reader who doubles their CLO dose chasing an omega-3 target, adds a multivitamin containing 750-3,000 mcg retinol, and eats liver-pâté or beef-liver routinely, and accumulates a chronic preformed-retinol intake well above the IOM upper limit without symptoms — quietly raising fracture risk and (if pregnant) malformation risk Feskanich et al. 2002 Penniston and Tanumihardjo 2006.

Treating CLO as a heart-attack-prevention drug. The CLO dose range cannot replicate REDUCE-IT's 4 g/day pure-EPA effect Bhatt et al. 2019; the trials at CLO-comparable doses (1 g/day mixed EPA+DHA) are null on primary CV endpoints Manson et al. 2019 ASCEND 2018. The honest pitch for CLO is omega-3-status sufficiency plus vitamin D and (carefully) vitamin A, not pharmaceutical-grade cardiovascular protection.

alternatives

Decision tree from the same goal:

Just want omega-3 status, no vitamins: a refined, third-party-tested fish-body oil (anchovy/sardine), or an algal EPA/DHA product if vegan/vegetarian. Algal DHA-only products may under-deliver EPA.
Want pharmaceutical TG/cardiovascular dose: icosapent ethyl (prescription, USA/EU), 4 g/day — different regulatory category and different evidence base Bhatt et al. 2019.
Want vitamin D only: a standalone D₃ drop or capsule lets you titrate by 25-OH-D level without the vitamin A constraint. At high latitudes most adults need 1,000-2,000 IU/day to maintain adequacy through winter.
Want the traditional whole-food version with all three: CLO at 1 tsp/day is a coherent choice if vitamin A intake from other sources is low and the product is fresh and standardised.

practicalities

Cost is low — $20-100/year at typical dosing. Liquid CLO is cheaper per dose than capsules and easier to titrate; flavoured (lemon, mint, orange) products mask the taste effectively. Storage: opaque bottle, refrigerated, used within 60-90 days of opening; check for printed expiry and any "fresh-batch" indicator the manufacturer provides. The third-party freshness/quality marks worth looking for are the IFOS (International Fish Oil Standards) certification and GOED (Global Organization for EPA and DHA Omega-3) voluntary monograph compliance for oxidation values. Smell-test on first opening: neutral fishy is fine, paint or solvent notes are not.

history

CLO was the original treatment for nutritional rickets, used empirically in coastal northern Europe for centuries before its mechanism was understood. Its formal medical adoption traces to Manchester pediatrician Edward Mellanby's 1919-1922 dog experiments and the subsequent identification of vitamin D as the antirachitic factor. By the 1930s, CLO was a staple in pediatric practice across North America and northern Europe; the Norwegian government distributed it institutionally and the post-1945 UK welfare-food scheme included it. Adoption fell as fortified milk and standalone vitamin D supplements displaced it from the 1960s onward; refined fish oil rose in the 1990s with omega-3 enthusiasm. The current revival is a smaller, traditional-foods-coded niche.

stakes

Stakes are modest in either direction — this is not a fix-or-fail entry. At low latitudes, in a fish-eating population, with vitamin D adequate from sun, the marginal value of CLO is small. At high latitude in winter, in a low-fish diet, with deficient D status, the absence of CLO (or some functional equivalent) means months of suboptimal 25-OH-D, slower-resolving inflammation, and the slow background of fall and fracture risk in older readers that vitamin D adequacy partially blunts Bischoff-Ferrari et al. 2009. The stakes of over-supplementing with CLO — preformed vitamin A creep, especially stacked with multivitamins — are real but slow: bone-density and fracture-risk effects accumulate over years Feskanich et al. 2002.

payoff

The honest payoff is sufficiency, not transformation. A teaspoon a day in a deficient reader closes the omega-3 and vitamin D gap within weeks (omega-3 index rises into the 6-8% target range over 3-4 months; 25-OH-D into the >30 ng/mL range over 6-12 weeks at adequate dose). The functional payoffs that follow are downstream of those statuses: small reductions in joint stiffness in inflammatory conditions, lower triglycerides, fewer winter falls in older adults at risk, and (for the high-RA-dose use case specifically) the NSAID-sparing effect from Galarraga's trial Galarraga 2008.

out-of-scope

Adjacent entries that warrant separate treatment: vitamin D supplementation as a standalone decision (dose titration by 25-OH-D, not by daily IU); omega-3 index testing as a measurement; icosapent ethyl as a prescription cardiovascular intervention distinct from food-grade omega-3; fatty fish consumption as a dietary alternative to supplementation; retinol vs beta-carotene as competing sources of vitamin A activity.

The credibility range

Optimist case. CLO is one of the few traditional whole-food supplements whose mechanism is fully understood and whose three active fractions are independently evidence-backed. It is the cheapest, simplest way to cover omega-3, vitamin D, and vitamin A in a single daily dose. The dose evolved empirically over centuries to match a real metabolic need, and the Norwegian observational and intervention literature shows it works as a winter D supply at high latitude Brustad 2004. Maternal/infant CLO is one of the only nutritional interventions with a credible signal on type 1 diabetes risk in offspring Stene and Joner 2003. At RA-trial dose, it spares NSAIDs without disease loss Galarraga 2008. As long as the product is fresh and the user does not stack vitamin A from other sources, the safety profile is excellent.

Skeptic case. CLO is a 19th-century delivery vehicle whose original indication (rickets) is now better served by vitamin D drops, and whose omega-3 dose is below what modern cardiovascular trials require to show an effect. The contemporary high-dose omega-3 trials are heterogeneous: VITAL, ASCEND, and STRENGTH are all null at fish-oil-comparable doses 2019 2018 2020, and Cochrane's pooled estimate is "little or no effect" on mortality Abdelhamid 2020. The vitamin A payload introduces a real toxicity ceiling that fish-body oil avoids entirely. Oxidation quality control in the supplement industry is poor Albert 2015; many consumers are taking a partially rancid product. For most modern users, a tested fish-body oil plus a separate vitamin D supplement is mechanistically equivalent, cheaper to titrate, and safer.

Author's call. CLO is a reasonable but not dominant choice for the specific user profile it actually fits: someone who wants a single traditional product covering omega-3, D, and A; who lives at moderate-to-high latitude or has documented winter D insufficiency; who does not stack other retinol sources; and who buys a freshness-tested, third-party-verified product and refrigerates it. For nearly everyone else — pregnancy, multivitamin users, those seeking pharmaceutical TG or cardiovascular effects, those who want flexible dose titration — the decomposed strategy (refined fish or algal oil + vitamin D drops, with retinol-free A) is the safer, more flexible, evidence-aligned choice. The overall evidence rating is moderate (substantial for the individual nutrients, weaker for CLO as a packaged product) and controversy is genuine but bounded — practitioners do not split into opposed camps on the substance itself, only on whether the whole-food framing meaningfully outperforms the decomposed alternative.

Stakeholder and incentive map

Commercial: traditional CLO brands (Møller's, Lysi, Carlson, Nordic Naturals, Rosita) compete on freshness claims, sourcing provenance, "high-vitamin" formulations, and certification. Refined fish-oil and pharmaceutical EPA producers (Amarin/Vascepa) compete against the CLO category on purity and dose.
Cultural / community: Weston A. Price Foundation and adjacent traditional-foods communities promote CLO heavily, often arguing for fermented or "high-vitamin" preparations over standardised products. The signal from this camp on the specific superiority of fermented/raw CLO is not supported by independent quality testing.
Professional: mainstream cardiology has cooled on EPA+DHA supplementation for primary prevention after VITAL, ASCEND, and STRENGTH; the AHA advisory now restricts the indication to specific secondary-prevention settings Siscovick 2017. Pediatric and obstetric practice in Scandinavia continues to recommend CLO during winter for vitamin D coverage in infants.
Regulatory: the IOM/NAM upper intake limit of 3,000 mcg RAE/day for preformed vitamin A is the binding constraint on labelling; EU food-supplement regulation has tightened retinol caps in the past decade in response. GOED voluntary oxidation monographs are non-binding and inconsistently enforced.
Counter-incentive: standalone vitamin D suppliers and refined fish-oil suppliers each have a structural reason to undermine CLO's positioning; both have a partial point.

Population variability

Baseline omega-3 status. Heaviest responders are those with the lowest baseline EPA+DHA — non-fish-eaters, vegetarians. Fish-eating populations may see little incremental benefit.
Latitude and skin tone. Vitamin D contribution is most valuable at >40° latitude in winter, and in dark-skinned individuals at any latitude. At low latitude in fair-skinned outdoor workers, the D contribution is mostly redundant.
Age. Older adults benefit disproportionately on the fall-prevention axis Bischoff-Ferrari 2009; they also have the most to lose from the vitamin A hip-fracture risk if dosed too high Feskanich 2002. The dose window narrows in this group.
Pregnancy. Maternal CLO has plausible benefit (DHA accretion, D adequacy, possible offspring T1D signal) but carries the most acute vitamin A ceiling concern. A vitamin-A-free formulation or decomposed approach is the safer default.
Multivitamin users. Anyone taking a multivitamin containing retinol should subtract that contribution from the CLO budget; the most common failure is double-counting.
Iron overload / hemochromatosis. Vitamin A modestly enhances iron uptake; small but worth flagging.
Inflammatory arthritis. Strongest evidence-of-benefit subgroup beyond status correction Galarraga 2008.

Knowledge gaps

No modern head-to-head RCT compares CLO as a whole-food product to a refined fish-oil-plus-vitamin-D-plus-retinol-free-A regimen at matched EPA+DHA, on cardiovascular, bone, or all-cause endpoints.
The mechanistic question of whether EPA-only (icosapent ethyl) outperforms EPA+DHA in cardiovascular prevention — the REDUCE-IT vs STRENGTH discrepancy — remains unresolved and bears directly on CLO's dose-response interpretation.
The supposed benefit of fermented or unrefined CLO over standardised products has no controlled evidence; it would be cheap to study and has not been.
Maternal-CLO offspring effects (type 1 diabetes signal in Stene/Joner; birthweight signal in Olafsdottir) are observational; no RCT has powered a hard offspring endpoint.
Real-world product oxidation in current US/EU markets is underreported since Albert's 2015 study; consumer-grade ability to assess freshness remains poor.

Scope. The brief named six consequence areas: omega-3 status, vitamin A status, vitamin D status, cardiovascular/inflammatory markers, bone markers, and the vitamin-A ceiling plus oxidation. All six are covered end to end in the body, with the vitamin-A ceiling and oxidation foregrounded in failure-modes, contraindications, and protocol rather than buried as caveats. The CLO-vs-refined-fish-oil-vs-algal distinction the brief asked for is addressed primarily in mechanism, misconceptions, and alternatives.

Rating difficulties.

Longevity was the hardest score. The vitamin D fall-prevention contribution (Bischoff-Ferrari 2009) and the early-life T1D signal (Stene 2003) push toward a 2; the null modern cardiovascular trials at CLO-comparable dose (VITAL, ASCEND, Cochrane Abdelhamid 2020) push back; the vitamin A hip-fracture risk (Feskanich 2002) is a downside. Landed at 2 as "small additive effect" — defensible either way.
Evidence was scored 3 rather than 4 to reflect the gap between strong constituent-nutrient evidence and the much thinner direct-CLO-as-a-product evidence (one credible RA RCT, mostly observational Nordic cohorts otherwise). A 4 would over-flatter the packaged product.
Controversy landed at 2 — there's no paradigm fight, but the whole-food-vs-decomposed debate is genuine, and the REDUCE-IT/STRENGTH discrepancy creates real disagreement on the upstream omega-3 question.
Applicability scored 3 (large minority — broad enough that the supplement-aisle decision audience extends well past current CLO users, narrow enough that fish-eating low-latitude readers genuinely don't need it).

Hard editorial calls.

Chose not to break out a separate audience section for older adults despite the falls-prevention case being their strongest single payoff — folded into stakes and payoff instead, to avoid fragmenting an already-modest entry.
Pregnancy is handled as a contraindication with a switch-product recommendation rather than as a flat "don't take CLO." This reflects the modern reality that vitamin-A-stripped CLO formulations exist and the omega-3+D rationale is strong in pregnancy; flat avoidance would be wrong.
Did not call out specific brand names anywhere in the article body even where third-party tests (Albert 2015) have named brands; kept the guidance to the IFOS/GOED-certification level instead. The brand landscape shifts faster than the entry will be updated.
The dream narrative was written despite the entry scoring ~22 (below the 40 threshold for obligatory narrative) because the relief/clarity lever is genuinely the entry's strongest hook — readers come confused about CLO-vs-fish-oil and leave with a calibrated mental model. A flat-voiced dek would have undersold this.

Excluded deliberately.

Detailed cancer-prevention evidence — VITAL was null on cancer too; treating it as a CLO-relevant question would have been padding.
Eye health / AMD — DHA mechanism is real but the trial evidence (AREDS2's omega-3 arm was null on AMD progression) doesn't support a meaningful claim and isn't what the brief asked for.
Cognitive decline / dementia prevention — early omega-3 dementia-prevention enthusiasm has not survived the trial era; would have required its own treatment.
Pediatric URI prevention (Linday's CLO-plus-multivitamin work) — small studies, indirect to the adult-oriented framing.

Separate-entry candidates surfaced during the write.

Vitamin D supplementation as a standalone entry — needs the dose-by-blood-level framing this entry only gestures at.
Icosapent ethyl — the prescription EPA story is distinct enough to warrant its own treatment under a different action verb (decide rather than do).
Omega-3 index testing as a test-action entry.
Preformed vitamin A vs beta-carotene — the toxicity-ceiling story belongs in its own entry the next time vitamin A surfaces.

Future-link candidates. When the above exist, wire vitamin D supplementation, omega-3 index testing, and icosapent ethyl into the out-of-scope section and the related meta field; this entry currently leaves related empty because none of the target entries exist yet.

One concrete weakness. The vitamin-A-ceiling case rests heavily on Feskanich 2002 (Nurses' Health Study) and Penniston 2006 (mechanistic review). A 2017 meta-analysis softened the Feskanich signal somewhat; the entry treats the risk as real but does not over-quantify it. If a reviewer wants a more cautious framing on the hip-fracture link, that would be defensible.